Business Context and Reporting Period
This Form 8-K is a current report filed by Tenaya Therapeutics, Inc. (TNYA) on January 2, 2026, regarding events occurring on December 31, 2025. The filing addresses corporate governance changes rather than financial performance.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel change and contains no financial data.
Material Changes
The material change reported is the resignation of David Goeddel from the Board of Directors and all Board committees. The resignation is effective January 26, 2026, in connection with his retirement. The Company states the resignation was voluntary and did not result from any disagreement regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure.
Key Facts for Investors
- David Goeddel is retiring from the Board of Directors effective January 26, 2026.
- The resignation is voluntary and unrelated to any disputes with the Company.
- No financial results or operational updates are included in this specific filing.